Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00078455 · ClinicalTrials.gov registry record · Phase 2
Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
A Phase 2 study of Non-Small-Cell Lung Carcinoma, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Study locations
NCT00078455: Completed Phase 2 study of Non-Small-Cell Lung Carcinoma, sponsored by Genzyme, a Sanofi Company.
NCT00078455 is a Phase 2 study of Non-Small-Cell Lung Carcinoma that has completed, run by Genzyme, a Sanofi Company. The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00078455, a Phase 2 study of Non-Small-Cell Lung Carcinoma, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10
- Study locations
Study Summary
This is a Phase II, non-randomized, open label study of ILX651 in patients with locally advanced or metastatic non-small cell lung carcinoma (NSCLC). Approximately 60 patients will be enrolled in this study that is expected to last 18 months. All patients will be treated with ILX651 administered intravenously (IV) daily for 5 consecutive days once every 21 days. The primary objective of this study is to determine the overall response rate. The secondary objectives are to determine the progression free survival, duration of response, time to tumor progression, survival, safety/tolerability of ILX651, and to evaluate pharmacokinetic profile.
Conditions Studied
Interventions
- DRUG ILX651
Study Locations (10)
Texas
- US Oncology / Texas Cancer Center - Dallas
- Joe Arrington Cancer Center - Lubbock
- US Oncology / Tyler Cancer Center - Tyler
Arizona
- US Oncology/ Arizona Clinical Research Center - Tucson
California
- Cancer Institute Medical Group - Santa Monica
Colorado
- Anshutz Cancer Pavillion - Aurora
Florida
- US Oncology / Ocala Oncology - Ocala
Indiana
- US Oncology / Central Indiana Cancer Centers - Indianapolis
Louisiana
- Hematology and Oncology Specialists - New Orleans
Tennessee
- Sarah Cannon Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-12 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
What the finished NCT00078455 record still lists
NCT00078455 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which ILX651 is the first listed.
NCT00078455 lists 10 locations in 8 states (Texas, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT00078455 about?
NCT00078455 is a clinical study titled "Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma". This is a Phase II, non-randomized, open label study of ILX651 in patients with locally advanced or metastatic non-small cell lung carcinoma (NSCLC). Approximately 60 patients will be enrolled in this study that is expected to last 18 months. All patients will be treated with ILX651 administered int...
What is the current status of trial NCT00078455?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-12. Estimated completion is 2005-08.
What conditions does trial NCT00078455 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT00078455?
The interventions under investigation include: ILX651 (DRUG).
Who is sponsoring clinical trial NCT00078455?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00078455 being conducted?
This trial has 10 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
COMPLETED · Phase 2
-
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
COMPLETED · Phase 2
-
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
COMPLETED · Phase 2
-
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia